pegylated leptin receptor antagonist

Pegylated leptin receptor antagonists are synthetic *pegylated* (polyethylene glycol-conjugated) peptide or protein drugs designed to block the activity of the leptin receptor (ObR). By interfering with leptin signaling, these antagonists induce a reversible state of leptin deficiency. Pegylation extends the circulating half-life of the molecule, increases stability, and decreases proteolytic degradation, improving the effectiveness of these agents in vivo. Pegylated leptin receptor antagonists have been studied mainly in preclinical and early clinical settings for their ability to increase appetite and body weight (by inducing functional leptin deficiency) and as experimental therapies to block leptin-ObR signaling in cancer (notably, breast cancer)[1][2][3][5]. Several variants exist, including antagonistic mutants of leptin and peptide fragments (such as LDFI and LPrA2) that are pegylated for increased bioavailability and efficacy. Research use includes obesity, metabolic disease models, and cancer models, but no agent is currently approved for clinical use. These antagonists are typically recombinant proteins or synthetic peptides.

Other names

pegylated leptin antagonistLDFI-PEGPEG-LDFIPEG-LPrA2PEG-LPrA-2PEG-LPrA 2PEG-OBleptin pegylated super antagonist